ClinicalTrials.gg
CompletedNCT01023581AM7DUpdated Mar 26, 2013Results posted

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

A Phase 3 interventional study of Alogliptin and Metformin in Diabetes Mellitus, Type 2, sponsored by Takeda. Completed at 201 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-03-26.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
784
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.

Enrollment
7th of 39
784 · median 329
Started
2009
with 4 others
Phase 3
16 of 39
none open now
Registered
16th of 39
by date
Lead sponsor
30 of 39
Takeda

Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 5 that started in 2009, is one of 16 in phase 3, and was the 16th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About alogliptin

alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.

Read the detailed description

There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% are type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected.

Metformin is the usual choice of first-line therapy for type 2 diabetes. Metformin targets insulin resistance in type 2 diabetes by inhibiting hepatic glucose production and stimulating glucose uptake in skeletal muscle and adipose tissue, which results in a long-term glucose-lowering effect.

Alogliptin is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes mellitus. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic (glucose) control in patients with type 2 diabetes.

Based on the potential, complimentary mechanisms of action of alogliptin and metformin, this study will compare the safety and efficacy of alogliptin and metformin (SYR-322MET) on improving glycemic control in patients with type 2 diabetes mellitus who are inadequately controlled by diet adjustment and exercise alone.

Participants taking part in this study will receive dietary and exercise coaching, and will monitor their own blood glucose concentrations with a home glucose monitor. Participants will also be required to maintain a hypoglycemic diary throughout the course of the study. Participation in this study is expected to last up to 34 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Type 2 Diabetes mellitus
  • Non-insulin dependent diabetes mellitus
  • Drug Therapy
  • Hypoglycemia,
  • Hyperglycemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has historical diagnosis of Type 2 Diabetes Mellitus.
  • Has been treated with diet and exercise for at least 2 months prior to Screening, and has a Glycosylated concentration between 7.5% and 10.0%, inclusive at Screening.
  • Has received less than 7 days of any antidiabetic medication within 2 months prior to Screening.
  • greater than or equal to 23 kg/m\^2 and less than or equal to 45 kg/m\^2 (except for Asian or Asian-descendant subjects for whom the range is between 20 and 35 kg/ m\^2, inclusive).
  • Fasting C-peptide concentration greater than or equal to 0.8 ng/mL.
  • Regularly using other, non-excluded, medications must be on a stable dose for at least the 4 weeks prior to Screening.
  • Females of and males who are sexually active agree to routinely use adequate from Screening throughout the duration of the study.
  • Able and willing to monitor their own blood glucose concentrations with a home glucose monitor and complete patient diaries.

Exclusion criteria

Exclusion Criteria:

  • less than 12 g/dL for males and less than 10 g/dL for females at Screening Visit.
  • Has a history of any hemoglobinopathy that may affect determination of Glycosylated Hemoglobin.
  • Has a history of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
  • Has a history of treatment for diabetic gastric paresis, gastric banding, or gastric bypass surgery.
  • Has a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.
  • Has systolic blood pressure greater than or equal to 150 mmHg and /or diastolic pressure greater than or equal to 90 mmHg at Screening visit.
  • Has Class III to IV heart failure.
  • Has a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 90 days prior to Screening.
  • Has greater than 3 times the at Screening.
  • Has a history of alcohol or substance abuse with the 2 years prior to Screening.
  • Serum creatinine greater than or equal to 1.5 mg/dL for males and greater than or equal to 1.4 mg/dL for females.
  • Has history of cancer, other than squamous cell or basal cell carcinoma of the skin that has not been in full remission for at least 5 years prior to Screening.
  • Has a history of infection with , virus or virus.
  • Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
  • Has received any drug within the 90 days prior to Screening.
  • Has a history of or allergy to alogliptin, other DPP-4 inhibitors, metformin or related compounds.
  • Has used oral or systematically injected or weight loss drugs prior to 2 months to screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
784 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.

    Drug: Alogliptin Placebo · Drug: Metformin Placebo

  • Experimental
    Alogliptin 25 QD

    Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Metformin Placebo

  • Experimental
    Alogliptin 12.5 BID

    Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Metformin Placebo

  • Active comparator
    Metformin 500 BID

    Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.

    Drug: Metformin · Drug: Alogliptin Placebo

  • Active comparator
    Metformin 1000 BID

    Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.

    Drug: Metformin · Drug: Alogliptin Placebo

  • Experimental
    Alogliptin 12.5 BID + Metformin 500 BID

    Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Metformin

  • Experimental
    Alogliptin 12.5 BID + Metformin 1000 BID

    Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Metformin

Interventions

  • Alogliptin tablets.

    Also known as: SYR-322

  • Metformin capsules

    Also known as: Glucophage, Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Dianben, Diabex, Diaformin

  • DrugAlogliptin Placebo

    Alogliptin placebo-matching tablets.

  • DrugMetformin Placebo

    Metformin placebo-matching capsules.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26

    The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).

    Time frame: Baseline and Week 26.

Secondary outcomes

  1. Change From Baseline in HbA1c Over Time

    The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.

    Time frame: Baseline and Weeks 4, 8, 12, 16, and 20.

  2. Change From Baseline in Fasting Plasma Glucose Over Time

    The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.

07

Results

Posted Mar 26, 2013

Participant flow

Participants took part in the study at 198 investigative sites worldwide from 16 November 2009 to 30 June 2011.

Participant flow — Overall Study
MilestonePlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BID
Started109112113114111111114
Received study treatment106112110109111106114
Completed74897194959294
Not completed35234220161920
Withdrew: Adverse event44732511
Withdrew: Major protocol deviation2030000
Withdrew: Lost to follow-up4872522
Withdrew: Withdrawal by subject1381610685
Withdrew: Pregnancy0002010
Withdrew: Lack of efficacy9362121
Withdrew: Physician decision2021111
Withdrew: Other1010100

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26

The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).

Time frame:
Baseline and Week 26.
Reported as:
Least squares mean · percentage glycosylated hemoglobin
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26
percentage glycosylated hemoglobinPlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BID
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 260.15 ± 0.094-0.52 ± 0.094-0.56 ± 0.093-0.65 ± 0.094-1.11 ± 0.092-1.22 ± 0.094-1.55 ± 0.090
Statistical analysis
  • Alogliptin 12.5 BID vs Alogliptin 12.5 BID + Metformin 500 BID · ANCOVA · p = <0.001 (For each set of comparisons in the primary analysis, the null hypothesis was rejected only if both comparisons between a combination and its constituent doses were statistically significant at the 2-sided 2.5% level.) · Ls mean difference: -0.67 · 95% CI -0.96 to -0.37ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate.
  • Metformin 500 BID vs Alogliptin 12.5 BID + Metformin 500 BID · ANCOVA · p = <0.001 · Ls mean difference: -0.57 · 95% CI -0.87 to -0.27ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate
  • Alogliptin 12.5 BID vs Alogliptin 12.5 BID + Metformin 1000 BID · ANCOVA · p = <0.001 · Ls mean difference: -1.00 · 95% CI -1.29 to -0.71ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate.
  • Metformin 1000 BID vs Alogliptin 12.5 BID + Metformin 1000 BID · ANCOVA · p = <0.001 · Ls mean difference: -0.44 · 95% CI -0.73 to -0.16ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate.
SecondaryChange From Baseline in HbA1c Over Time

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.

Time frame:
Baseline and Weeks 4, 8, 12, 16, and 20.
Reported as:
Least squares mean · percentage glycosylated hemoglobin
Change From Baseline in HbA1c Over Time
percentage glycosylated hemoglobinPlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BID
Week 4 (n=95, 97, 89, 94, 102, 94, 101)0.09 ± 0.058-0.34 ± 0.057-0.42 ± 0.060-0.37 ± 0.058-0.58 ± 0.056-0.70 ± 0.058-0.75 ± 0.056
Week 8 (n=102, 104, 104, 103, 108, 102, 111)0.08 ± 0.073-0.51 ± 0.073-0.58 ± 0.072-0.59 ± 0.073-0.86 ± 0.071-1.08 ± 0.073-1.17 ± 0.070
Week 12 (n=102, 104, 104, 103, 108, 102, 111)0.12 ± 0.081-0.53 ± 0.080-0.62 ± 0.080-0.68 ± 0.081-1.02 ± 0.079-1.22 ± 0.081-1.40 ± 0.078
Week 16 (n=102, 104, 104, 103, 108, 102, 111)0.13 ± 0.087-0.58 ± 0.087-0.63 ± 0.086-0.72 ± 0.087-1.09 ± 0.085-1.26 ± 0.087-1.50 ± 0.084
Week 20 (n=102, 104, 104, 103, 108, 102, 111)0.12 ± 0.092-0.57 ± 0.091-0.59 ± 0.091-0.68 ± 0.092-1.14 ± 0.089-1.25 ± 0.092-1.54 ± 0.088
SecondaryChange From Baseline in Fasting Plasma Glucose Over Time

The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose Over Time
mg/dLPlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BID
Week 1 (n=102, 103, 94, 95, 104, 101, 109)5.7 ± 3.40-3.9 ± 3.38-11.9 ± 3.54-12.6 ± 3.52-23.1 ± 3.36-32.7 ± 3.41-36.3 ± 3.29
Week 2 (n=105, 112, 105, 102, 108, 106, 111)4.6 ± 3.58-7.4 ± 3.46-11.6 ± 3.58-14.5 ± 3.63-22.2 ± 3.53-34.5 ± 3.56-43.6 ± 3.48
Week 4 (n=105, 112, 106, 106, 110, 106, 111)7.2 ± 3.69-11.5 ± 3.57-16.6 ± 3.67-16.9 ± 3.67-29.0 ± 3.60-37.6 ± 3.67-44.1 ± 3.58
Week 8 (n=105, 112, 106, 106, 110, 106, 112)7.1 ± 4.00-10.9 ± 3.87-12.1 ± 3.98-11.8 ± 3.98-30.7 ± 3.91-32.9 ± 3.98-43.8 ± 3.87
Week 12 (n=105, 112, 106, 106, 110, 106, 112)11.6 ± 4.16-9.7 ± 4.03-14.7 ± 4.14-14.0 ± 4.14-30.7 ± 4.06-31.6 ± 4.14-44.7 ± 4.03
Week 16 (n=105, 112, 106, 106, 110, 106, 112)10.1 ± 4.17-7.1 ± 4.04-14.7 ± 4.15-13.3 ± 4.15-33.5 ± 4.07-35.9 ± 4.15-47.7 ± 4.04
Week 20 (n=105, 112, 106, 106, 110, 106, 112)8.7 ± 4.36-9.2 ± 4.22-12.3 ± 4.34-10.9 ± 4.34-35.1 ± 4.25-33.8 ± 4.34-44.6 ± 4.22
Week 26 (n=105, 112, 106, 106, 110, 106, 112)12.4 ± 4.52-6.1 ± 4.37-9.7 ± 4.49-11.5 ± 4.49-31.9 ± 4.41-31.7 ± 4.49-45.9 ± 4.37

Adverse events

Collected over Adverse events that occurred after the first dose of double-blind study medication and within 14 days after the last dose of double-blind study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/106 (2.8%)50/106 (47.2%)
Alogliptin 25 QD—1/112 (0.9%)38/112 (33.9%)
Alogliptin 12.5 BID—4/110 (3.6%)34/110 (30.9%)
Metformin 500 BID—3/109 (2.8%)44/109 (40.4%)
Metformin 1000 BID—2/111 (1.8%)43/111 (38.7%)
Alogliptin 12.5 BID + Metformin 500 BID—2/106 (1.9%)40/106 (37.7%)
Alogliptin 12.5 BID + Metformin 1000 BID—2/114 (1.8%)37/114 (32.5%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BID
Myocardial ischaemiaCardiac disorders1/1060/1120/1100/1090/1110/1060/114
TremorNervous system disorders1/1060/1120/1100/1090/1110/1060/114
Non-cardiac chest painGeneral disorders0/1060/1120/1100/1090/1111/1060/114
HyperglycaemiaMetabolism and nutrition disorders1/1060/1120/1100/1090/1110/1060/114
DelusionPsychiatric disorders0/1060/1120/1100/1090/1111/1060/114
Angina pectorisCardiac disorders0/1060/1120/1101/1090/1110/1060/114
Ankle fractureInjury, poisoning and procedural complications0/1060/1120/1101/1090/1110/1060/114
Alveolitis allergicRespiratory, thoracic and mediastinal disorders0/1060/1120/1101/1090/1110/1060/114
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders0/1060/1120/1101/1090/1110/1060/114
PneumoniaInfections and infestations0/1060/1121/1100/1090/1110/1060/114
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BID
HyperglycaemiaMetabolism and nutrition disorders28/10619/11213/11019/1099/1118/1061/114
DiarrhoeaGastrointestinal disorders3/1061/1123/1104/10910/1116/1068/114
Creatinine renal clearance decreasedInvestigations4/1061/1124/1100/1096/1115/1069/114
Upper respiratory tract infectionInfections and infestations3/1063/1123/1104/1093/1118/1062/114
HeadacheNervous system disorders3/1066/1125/1108/1094/1117/1066/114
HypertensionVascular disorders5/1063/1122/1106/1091/1115/1068/114
DyspepsiaGastrointestinal disorders3/1060/1121/1100/1092/1110/1068/114
DyslipidaemiaMetabolism and nutrition disorders6/1061/1122/1107/1096/1116/1062/114
NasopharyngitisInfections and infestations2/1067/1121/1102/1094/1113/1062/114
HypertriglyceridaemiaMetabolism and nutrition disorders3/1063/1121/1103/1096/1116/1061/114

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BIDTotal
Mean53.1 ± 9.6052.6 ± 9.3853.7 ± 9.7054.6 ± 10.2052.6 ± 11.3053.7 ± 11.5954.6 ± 10.4253.5 ± 10.33
Age, Customized
Age, Customized(participants)PlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BIDTotal
<65 years1001039695949196675
≥65 years991719172018109
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BIDTotal
Female54645067606352410
Male55486347514862374
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BIDTotal
Hispanic or Latino45434345424539302
Not Hispanic or Latino64697069696675482
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BIDTotal
American Indian or Alaska Native585369541
Asian20172119202026143
Native Hawaiian or Other Pacific Islander00100001
Black or African American833666537
White76848385797678561
Multiracial00010001
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BIDTotal
Mean31.15 ± 5.26930.81 ± 5.21930.36 ± 5.15930.19 ± 4.84230.51 ± 5.04330.92 ± 5.35331.04 ± 5.37530.71 ± 5.173
Diabetes Duration
Diabetes Duration(years)PlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BIDTotal
Mean4.25 ± 4.7783.65 ± 4.1193.97 ± 4.8003.78 ± 3.9044.08 ± 4.5874.13 ± 4.7774.22 ± 4.9724.01 ± 4.563
Baseline HbA1c
Baseline HbA1c(participants)PlaceboAlogliptin 25 QDAlogliptin 12.5 BIDMetformin 500 BIDMetformin 1000 BIDAlogliptin 12.5 BID + Metformin 500 BIDAlogliptin 12.5 BID + Metformin 1000 BIDTotal
≤8.5%65676767666667465
>8.5%44454647454547319
08

Study locations

201 sites
  • Dothan, Alabama, United States
  • Muscle Shoals, Alabama, United States
  • Pell City, Alabama, United States
  • Chandler, Arizona, United States
  • Mesa, Arizona, United States
  • Phoenix, Arizona, United States
  • Sierra Vista, Arizona, United States
  • Tempe, Arizona, United States
  • Little Rock, Arkansas, United States
  • Searcy, Arkansas, United States
  • Tempe, Arkansas, United States
  • Anaheim, California, United States
  • Buena Park, California, United States
  • Cathedral City, California, United States
  • National City, California, United States
  • Pismo Beach, California, United States
  • Roseville, California, United States
  • Santa Ana, California, United States
  • Colorado Springs, Colorado, United States
  • Boca Raton, Florida, United States
  • Bradenton, Florida, United States
  • Cutler Bay, Florida, United States
  • Hialeah, Florida, United States
  • Lauderdale Lakes, Florida, United States
  • Miami, Florida, United States
  • Ocala, Florida, United States
  • Opa Locka, Florida, United States
  • Orlando, Florida, United States
  • Panama City, Florida, United States
  • Pembroke Pines, Florida, United States
  • Atlanta, Georgia, United States
  • Blue Ridge, Georgia, United States
  • Decatur, Georgia, United States
  • Lawrenceville, Georgia, United States
  • Hayden Lake, Idaho, United States
  • Chicago, Illinois, United States
  • Melrose Park, Illinois, United States
  • La Porte, Indiana, United States
  • Mishawaka, Indiana, United States
  • Council Bluffs, Iowa, United States
  • Dubuque, Iowa, United States
  • Topeka, Kansas, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Marrero, Louisiana, United States
  • Oxon Hill, Maryland, United States
  • North Dartmouth, Massachusetts, United States
  • Dearborn, Michigan, United States
  • Flint, Michigan, United States
  • Kalamazoo, Michigan, United States
  • Picayune, Mississippi, United States
  • St. Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Henderson, Nevada, United States
  • Las Vegas, Nevada, United States
  • Brick, New Jersey, United States
  • Elizabeth, New Jersey, United States
  • North Massapequa, New York, United States
  • Asheville, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Greensboro, North Carolina, United States
  • Mooresville, North Carolina, United States
  • Fargo, North Dakota, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Gallipolis, Ohio, United States
  • Mason, Ohio, United States
  • Maumee, Ohio, United States
  • Norman, Oklahoma, United States
  • Oklahoma City, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Altoona, Pennsylvania, United States
  • Bensalem, Pennsylvania, United States
  • Downingtown, Pennsylvania, United States
  • Fleetwood, Pennsylvania, United States
  • Perkasie, Pennsylvania, United States
  • Shippensburg, Pennsylvania, United States
  • Tipton, Pennsylvania, United States
  • Uniontown, Pennsylvania, United States
  • Columbia, South Carolina, United States
  • Greenville, South Carolina, United States
  • Murrells Inlet, South Carolina, United States
  • North Myrtle Beach, South Carolina, United States
  • Taylors, South Carolina, United States
  • Brentwood, Tennessee, United States
  • Bristol, Tennessee, United States
  • Crossville, Tennessee, United States
  • Johnson City, Tennessee, United States
  • McKenzie, Tennessee, United States
  • Spring Hill, Tennessee, United States
  • Carrollton, Texas, United States
  • Dallas, Texas, United States
  • Deer Park, Texas, United States
  • El Paso, Texas, United States
  • Houston, Texas, United States
  • Hurst, Texas, United States
  • Katy, Texas, United States
  • Odessa, Texas, United States
  • San Antonio, Texas, United States
  • Schertz, Texas, United States

Showing the first 100 of 201 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014 Jul;16(7):613-21. doi: 10.1111/dom.12258. Epub 2014 Feb 12. PubMed 24400655 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2009
First posted
Dec 2, 2009
Start
Nov 2009
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Mar 26, 2013
Last update
Mar 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01023581
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 2, 2009
Start date
Nov 2009
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Mar 26, 2013
Last update
Mar 26, 2013

Study contacts

Vice President, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alogliptin · Metformin

Start the discussion